Korean J Med.
2023 Apr;98(2):59-63. 10.3904/kjm.2023.98.2.59.
SGLT2 Inhibitors: Emerging Drugs in Heart Failure
- Affiliations
-
- 1Department of Cardiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
- KMID: 2541451
- DOI: http://doi.org/10.3904/kjm.2023.98.2.59
Abstract
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of diabetes medications that have demonstrated the potential to improve outcomes for heart failure (HF) patients. Although they were originally developed to treat diabetes, clinical trials have demonstrated their ability to both reduce the risk and improve the prognosis of HF. SGLT2 inhibitors have unique mechanisms of action, including improvement of water retention and promotion of lipolysis, which contribute to their effectiveness in treating HF. They are considered essential primary treatment options for patients with HF, regardless of diabetes status and ejection fraction. Overall, the use of SGLT2 inhibitors in patients with HF is expected to increase in the future and may further improve treatment outcomes for HF patients.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
- SGLT2 Inhibitors and Diabetes: Where Does It Come from and Where Does It Go?
- Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors
- SGLT2 Inhibitors in the Cardiovascular Disease
- Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials
